WO2015145388A3 - Methods of treating colorectal cancers harboring upstream wnt pathway mutations - Google Patents
Methods of treating colorectal cancers harboring upstream wnt pathway mutations Download PDFInfo
- Publication number
- WO2015145388A3 WO2015145388A3 PCT/IB2015/052245 IB2015052245W WO2015145388A3 WO 2015145388 A3 WO2015145388 A3 WO 2015145388A3 IB 2015052245 W IB2015052245 W IB 2015052245W WO 2015145388 A3 WO2015145388 A3 WO 2015145388A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- wnt pathway
- methods
- colorectal cancers
- treating colorectal
- pathway mutations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
Abstract
The present invention relates to a method of treating patients suffering from colorectal cancer, more specifically BRAF V600E -mutant or BRAF wild type, but KRAS wild type and microsatellite-unstable colorectal cancer by using a Wnt pathway inhibitor or a combination comprising a Wnt pathway inhibitor and either a BRAF inhibitor, or an EGFR inhibitor, or both. The disclosure also relates to corresponding pharmaceutical formulations, uses, methods, combinations, and related disclosure embodiments.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461971162P | 2014-03-27 | 2014-03-27 | |
US61/971,162 | 2014-03-27 | ||
US201562119939P | 2015-02-24 | 2015-02-24 | |
US62/119,939 | 2015-02-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015145388A2 WO2015145388A2 (en) | 2015-10-01 |
WO2015145388A3 true WO2015145388A3 (en) | 2016-01-28 |
Family
ID=52815064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2015/052245 WO2015145388A2 (en) | 2014-03-27 | 2015-03-26 | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW201620548A (en) |
WO (1) | WO2015145388A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190019171A (en) * | 2016-06-22 | 2019-02-26 | 노파르티스 아게 | Wnt inhibitors for use in the treatment of fibrosis |
WO2019245460A1 (en) * | 2018-06-21 | 2019-12-26 | National University Of Singapore | Stratifying cancer patients harbouring oncogenic mutations in the e3 ubiquitin ligase rnf43 |
CN113307882B (en) * | 2021-05-12 | 2022-12-20 | 东北大学 | Fusion protein SZ1 for targeted therapy of colorectal cancer caused by over-activation of Rspo and coupled nano-drug thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120059021A1 (en) * | 2008-11-11 | 2012-03-08 | University Of Washington | Compositions and methods for treating cancer and methods for predicting a response to such treatments |
WO2013086260A2 (en) * | 2011-12-09 | 2013-06-13 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of cancer |
WO2013130364A1 (en) * | 2012-02-28 | 2013-09-06 | Novartis Ag | Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status |
WO2014025688A1 (en) * | 2012-08-07 | 2014-02-13 | Novartis Ag | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
TW225528B (en) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
DK0817775T3 (en) | 1995-03-30 | 2001-11-19 | Pfizer | quinazoline |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
IL122855A (en) | 1995-07-06 | 2004-08-31 | Novartis Ag | N-PHENYL (ALKYL)-7H-PYRROLO [2,3-d] PYRIMIDIN-4-AMINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
PT892789E (en) | 1996-04-12 | 2002-07-31 | Warner Lambert Co | IRREVERSIVE INHIBITORS OF TYROSINE KINASES |
EP0907642B1 (en) | 1996-06-24 | 2005-11-02 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
AU4342997A (en) | 1996-09-13 | 1998-04-02 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
CO4940418A1 (en) | 1997-07-18 | 2000-07-24 | Novartis Ag | MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
JO3002B1 (en) | 2009-08-28 | 2016-09-05 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
JO3300B1 (en) | 2012-06-06 | 2018-09-16 | Novartis Ag | Compounds and compositions for modulating egfr activity |
-
2015
- 2015-03-26 WO PCT/IB2015/052245 patent/WO2015145388A2/en active Application Filing
- 2015-03-27 TW TW104110103A patent/TW201620548A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120059021A1 (en) * | 2008-11-11 | 2012-03-08 | University Of Washington | Compositions and methods for treating cancer and methods for predicting a response to such treatments |
WO2013086260A2 (en) * | 2011-12-09 | 2013-06-13 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of cancer |
WO2013130364A1 (en) * | 2012-02-28 | 2013-09-06 | Novartis Ag | Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status |
WO2014025688A1 (en) * | 2012-08-07 | 2014-02-13 | Novartis Ag | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
Non-Patent Citations (8)
Title |
---|
GIORDANO CAPONIGRO: "Abstract 2337: Efficacy of the RAF/PI3K[alpha]/anti-EGFR triple combination LGX818 + BYL719 + cetuximab in BRAFV600E colorectal tumor models.", 6 April 2013 (2013-04-06), XP055200917, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/73/8_Supplement/2337.short> [retrieved on 20150708] * |
ISAAC SCHAMALE: "Wnt Signaling Pathway Inhibition Enhances Efficacy of Cetuximab", OTOLARYNGOLOGY -- HEAD AND NECK SURGERY, 1 September 2013 (2013-09-01), pages 81 - 82, XP055219423, Retrieved from the Internet <URL:http://oto.sagepub.com/content/149/2_suppl/P81.3> [retrieved on 20151008] * |
J. LIU ET AL: "Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 110, no. 50, 25 November 2013 (2013-11-25), pages 20224 - 20229, XP055121007, ISSN: 0027-8424, DOI: 10.1073/pnas.1314239110 * |
K. TAKADA ET AL: "Targeted Disruption of the BCL9/ -Catenin Complex Inhibits Oncogenic Wnt Signaling", SCIENCE TRANSLATIONAL MEDICINE, vol. 4, no. 148, 22 August 2012 (2012-08-22), pages 148ra117 - 148ra117, XP055150823, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.3003808 * |
LUCA MOLOGNI ET AL: "Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells", PLOS ONE, vol. 7, no. 12, 5 December 2012 (2012-12-05), pages e51449, XP055200401, DOI: 10.1371/journal.pone.0051449 * |
M. CASAS-SELVES ET AL: "Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition", CANCER RESEARCH, vol. 72, no. 16, 15 August 2012 (2012-08-15), US, pages 4154 - 4164, XP055218639, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-11-2848 * |
T. L. BIECHELE ET AL: "Wnt/ -Catenin Signaling and AXIN1 Regulate Apoptosis Triggered by Inhibition of the Mutant Kinase BRAFV600E in Human Melanoma", SCIENCE SIGNALING, vol. 5, no. 206, 10 January 2012 (2012-01-10), US, pages ra3 - ra3, XP055218840, ISSN: 1945-0877, DOI: 10.1126/scisignal.2002274 * |
X. JIANG ET AL: "Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 110, no. 31, 11 July 2013 (2013-07-11), pages 12649 - 12654, XP055200712, ISSN: 0027-8424, DOI: 10.1073/pnas.1307218110 * |
Also Published As
Publication number | Publication date |
---|---|
WO2015145388A2 (en) | 2015-10-01 |
TW201620548A (en) | 2016-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY196830A (en) | Kras g12c inhibitors and methods of using the same | |
PH12016502453A1 (en) | Heteroaryl compounds for kinase inhibition | |
EA201992781A1 (en) | G12C KRAS INHIBITORS AND WAYS OF THEIR APPLICATION | |
NZ718190A (en) | Substituted quinazolines for inhibiting kinase activity | |
EP3484504A4 (en) | Compounds, compositions, and methods for the treatment of disease | |
AU2015237050A8 (en) | Quinoline derivatives as SMO inhibitors | |
EP3675859A4 (en) | Compounds, compositions, and methods for the treatment of disease | |
WO2014116833A3 (en) | Compositions and methods for detecting neoplasia | |
EP3800248A3 (en) | Crispr-cas-related methods, compositions and components for cancer immunotherapy | |
EA201692472A1 (en) | CONNECTIONS FOR THE TREATMENT OF BRAIN CANCER | |
AU2016246521A8 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
WO2014138364A3 (en) | Methods of treating and preventing cancer drug resistance | |
EP2996721A4 (en) | Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer | |
WO2014205266A3 (en) | Compositions and methods for detecting and treating glioblastoma | |
MX2016014436A (en) | Heterocyclyl-butanamide derivatives. | |
MX2018006700A (en) | Aza-benzimidazole inhibitors of pad4. | |
MX2019010149A (en) | Inhibition of smarca2 for treatment of cancer. | |
EP3471722A4 (en) | Compounds, compositions and methods for prevention and/or treatment of cancer | |
MX2018005987A (en) | Heterocyclic compounds for the treatment of disease. | |
MX370897B (en) | Fused bicyclic compounds for the treatment of disease. | |
EP3576792A4 (en) | Methods, compositions, and kits for treatment of cancer | |
WO2015145388A3 (en) | Methods of treating colorectal cancers harboring upstream wnt pathway mutations | |
EP3292218A4 (en) | Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer | |
EP4218789A3 (en) | Compositions for colon cleansing and the treatment of gastrointestnal disorders | |
EA201691896A1 (en) | CONNECTIONS AND METHODS OF THEIR APPLICATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15714960 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15714960 Country of ref document: EP Kind code of ref document: A2 |